Subdermal Contraceptive Implants Market Segmentation:
Product Segment Analysis
The etonogestrel implant segment is estimated to hold 66% share of the global subdermal contraceptive implants market during the forecast period. Etonogestrel implant is a hormonal birth control method that comes in the form of a flexible plastic matchstick-sized rod. Additionally, the U.S. Food and Drug Administration has given the etonogestrel subdermal implant approval for contraception for up to three years as a highly effective contraceptive option for women. Moreover, the etonogestrel implant has a failure rate of less than 1%, making it more efficient than female sterilization.
Application Segment Analysis
Subdermal contraceptive implants market from the hospital segment is set to garner a notable share shortly. Subdermal contraceptive implant procedure is usually performed within the hospital premises whereby the gynecologist places the implant in the non-dominant arm, typically, in the consultation room by using a local anesthetic. Besides this, sometimes there may be a need for specialized procedures, including hospital surgery if it gets difficult to remove the implant, or it cannot be found.
Type Segment Analysis
Subdermal contraceptive implants market from the biodegradable segment is set to garner significant share by the year 2035. Levonorgestrel (LNG) biodegradable subcutaneous implants have emerged as the most promising long-term contraceptive methods as they release a contraceptive steroid for a predetermined amount of time before dissolving. Besides this, a subdermal biodegradable contraceptive implant is used to provide secure and reliable contraception, as it is a low-cost, biodegradable implant system in the form of a subdermal pellet, is extremely adaptable, and does not need to be surgically removed.
Our in-depth analysis of the global subdermal contraceptive implants market includes the following segments:
|
Product |
|
|
Application |
|
|
Type |
|
